Brain-derived neurotrophic factor serum levels in genetically isolated populations: gender-specific association with anxiety disorder subtypes but not with anxiety levels or Val66Met polymorphism

Carlino, Davide; Francavilla, Ruggiero; Baj, Gabriele; Kułak, Karolina; D’Adamo, Pio; Ulivi, Sheila; Cappellani, Stefania; Gasparini, Paolo; Tongiorgi, Enrico

doi:10.7717/peerj.1252

Cited by 22 publications

(27 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…General anxiety disorder BDNF Plasma levels =vs. HCs, ↓ in females [220,221] No association with disorder severity [222] ↓ vs. HCs [210,223,224] ↑ vs. HCs, with normalization after remission [225] BDNF levels in the newborn's cord blood of women with GAD ↑ vs. HCs [226] NGF Serum levels =vs. HCs at baseline, ↑ after remission [227] GDNF Serum BDNF/GDNF levels ↓ vs. HCs [228] Panic disorders with or without agoraphobia BDNF Plasma levels =vs.…”

Section: Biomarker Findingmentioning

confidence: 98%

Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview

et al. 2020

View full text Add to dashboard Cite

Anxiety disorders are prevalent and highly disabling mental disorders. In recent years, intensive efforts focused on the search for potential neuroimaging, genetic, and peripheral biomarkers in order to better understand the pathophysiology of these disorders, support their diagnosis, and characterize the treatment response. Of note, peripheral blood biomarkers, as surrogates for the central nervous system, represent a promising instrument to characterize psychiatric disorders, although their role has not been extensively applied to clinical practice. In this report, the state of the art on peripheral biomarkers of DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) Anxiety Disorders is presented, in order to examine their role in the pathogenesis of these conditions and their potential application for diagnosis and treatment. Available data on the cerebrospinal fluid and blood-based biomarkers related to neurotransmitters, neuropeptides, the hypothalamic–pituitary–adrenal axis, neurotrophic factors, and the inflammation and immune system are reviewed. Despite the wide scientific literature and the promising results in the field, only a few of the proposed peripheral biomarkers have been defined as a specific diagnostic instrument or have been identified as a guide in the treatment response to DSM-5 Anxiety Disorders. Therefore, further investigations are needed to provide new biological insights into the pathogenesis of anxiety disorders, to help in their diagnosis, and to tailor a treatment.

show abstract

Section: Biomarker Findingmentioning

confidence: 98%

Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The authors also found that the difference between female and male patients could not be attributed to the presence of a specific subtype of anxiety as serum BDNF levels were similar across the subtypes, and thus peripheral BDNF measurements did not have the specificity to categorize anxiety disorders. Similarly, Carlino et al 36 analyzed serum BDNF levels in adult subjects with different anxiety disorder subtypes such as social and specific phobias, GAD and panic disorder in order to test whether serum BDNF levels could be a potential biomarker for different subtypes of anxiety disorders. No significant correlation between serum BDNF levels and anxiety disorders was found as a whole or as a single diagnostic category.…”

Section: Bdnf and The Vulnerability To Psychiatric Disordersmentioning

confidence: 99%

The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders

et al. 2016

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) regulates the survival and growth of neurons, and influences synaptic efficiency and plasticity. The human BDNF gene consists of 11 exons, and distinct BDNF transcripts are produced through the use of alternative promoters and splicing events. The majority of the BDNF transcripts can be detected not only in the brain but also in the blood cells, although no study has yet investigated the differential expression of BDNF transcripts at the peripheral level. This review provides a description of the human BDNF gene structure as well as a summary of clinical and preclinical evidence supporting the role of BDNF in the pathogenesis of psychiatric disorders. We will discuss several mechanisms as possibly underlying BDNF modulation, including epigenetic mechanisms. We will also discuss the potential use of peripheral BDNF as a biomarker for psychiatric disorders, focusing on the factors that can influence BDNF gene expression and protein levels. Within this context, we have also characterized, for we believe the first time, the expression of BDNF transcripts in the blood, with the aim to provide novel insights into the molecular mechanisms and signaling that may regulate peripheral BDNF gene expression levels.

show abstract

“…20 But Chen et al 31 have reported a significant decrease in serum levels of BDNF in GAD affected females. Additionally they reported that higher levels of trait anxiety were found in subjects bearing the Val/Val BDNF allele compared to Val/Met and Met/Met genotypes.…”

Section: ■ Resultsmentioning

confidence: 98%

“…25 Few studies have been conducted about serum BDNF as a biomarker in patients with anxiety disorders. 20 Finally, it should be noted that the Met allele of the BDNF Val66Met polymorphism has been implicated in anxiety in animal models. 30 The circadian-clock-related genes BCL2 and DRD2 were investigated in an association analysis to test whether they predispose to human anxiety disorders.…”

Section: ■ Resultsmentioning

confidence: 99%